New cocktail of drugs and vaccines takes on advanced ovarian cancer
NCT ID NCT07634094
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a new, intensive treatment plan for 28 people with advanced ovarian cancer. The approach combines chemotherapy given into the abdomen and vein, a special vaccine made from the patient's own immune cells, and the immunotherapy drug Keytruda. The goal is to see if this powerful mix can destroy more cancer before surgery and help keep the cancer away longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
A combination of chemotherapy drugs (paclitaxel and cisplatin), a chemokine modulatory regimen (rintatolimod and interferon-alpha), an autologous dendritic cell vaccine (αDC1), the immunotherapy drug pembrolizumab (Keytruda), and the anti-inflammatory drug celecoxib.
What this could lead to
If successful, this could lead to a more effective treatment approach for advanced ovarian cancer, potentially increasing the chance of eliminating all visible cancer before surgery and delaying cancer return.
What could go wrong
This is an early phase 2 trial with only 28 participants, so results may not apply to all patients. The combination of multiple strong treatments also raises the risk of serious side effects, and it is unknown if the added benefit will outweigh these risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UMPC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact